Palliative chemotherapy outcomes in patients with ECOG-PS higher than 1

Rafael Caires-Lima, Karolina Cayres, Bruno Mendonça Protásio, Inacelli Queiroz de Souza Caires, Júlia Andrade, Lucila Soares da Silva Rocha, Tiago Kenji Takahashi, Paulo M. Hoff, Gilberto de Castro, Milena Perez Mak

ecancermedicalscience · 2018 · 50 citations · 20 references

DOIFull text

Open access

Concepts

Abstract

PURPOSE: Although patients with incurable disease and Eastern Cooperative Oncology Group performance status (ECOG-PS ≥ 2) are underrepresented in clinical trials, they are frequently offered palliative chemotherapy (pCT) in daily clinical practice in order to improve symptoms and quality of life. In this case-control retrospective analysis, our goal was to identify factors associated with poorer survival and lack of benefit of pCT in this population. PATIENTS AND METHODS: We evaluated 2,514 patients who died between August 2011 and July 2012 in an academic cancer care institution and its hospice. A total of 301 patients with solid tumours and ECOG-PS ≥ 2 at prescription of pCT were selected for this case-control retrospective analysis. Cases were defined as patients who survived less than 90 days after the first cycle of first line pCT, and controls were those who had a longer survival. RESULTS: < 0.001) as independent predictors of 90-day mortality. CONCLUSIONS: The independent predictors of short survival (less than 3 months) after initiation of pCT in this population were ECOG-PS > 2 and elevated sCr. Therefore, patient selection is crucial, as pCT may be deleterious in ECOG-PS ≥ 2 pts.

References

20